Clinical Trials Browser

Rogaratinib × Clear all

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03762122 2022-11-09

Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)

Phase 2 Terminated

15 enrolled

Acrocephalosyndactylia

NCT03410693 2022-09-28

FORT-1

Phase 2/3 Completed

175 enrolled 19 charts

Genitourinary

Carcinoma, Transitional Cell

NCT04125693 2022-04-01

Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety

Phase 2 Completed

1 enrolled

BreastGenitourinaryHead & NeckThoracic

Acrocephalosyndactylia, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Neoplasms, Small Cell Lung Carcinoma

NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Phase 1 Completed

168 enrolled 59 charts

GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT03788603 2021-03-29

Rogaratinib (BAY1163877) in Chinese Patients

Phase 1 Completed

1 enrolled

Tumor-Agnostic

Neoplasms

NCT04040725 2019-12-17

Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression

Phase 2 Withdrawn

Genitourinary

Urinary Bladder Neoplasms

NCT02592785 2018-04-18

Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

9 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

FORT-2

Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)

FORT-1

Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Rogaratinib (BAY1163877) in Chinese Patients

Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression

Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors